Grufity logoGrufity logo

HZNP

100.88USD+0.59(+0.59%)Market Closed

Horizon Pharma PLC

Market Summary

USD100.88+0.59Market Closed
0.59%

HZNP Alerts

HZNP Stock Price

RSI Chart

Valuation

Market Cap

14.7B

Price/Earnings

19.22

Price/Sales

3.86

Price/Cashflow

10.4

MarketCap/EBT

19.46

Price/Sales

Profitability

EBT Margin

19.82%

Return on Equity

15.47%

Return on Assets

8.64%

Fundamentals

Revenue

Revenue (TTM)

3.7B

Revenue Y/Y

-10.77%

Revenue Q/Q

5.59%

Earnings

Earnings (TTM)

574.3M

Earnings Y/Y

-58.4%

Earnings Q/Q

122.78%

Price Action

52 Week Range

117.49
(Low)(High)

Last 7 days

30.1%

Last 30 days

59.7%

Last 90 days

68.1%

Trailing 12 Months

-4.3%

Financial Health

Current Ratio

4.05

Debt/Equity

0.52

Debt/Cashflow

0.55

Investor Care

Buy Backs (1Y)

0.09%

Diluted EPS (TTM)

2.44

Peers (Alternatives to Horizon Pharma)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
459.8B
96.0B
3.93% 16.04%
24
4.79
5.02% 7.14%
342.0B
29.2B
5.33% 50.68%
60.08
11.76
5.34% 1.02%
266.2B
99.7B
7.31% -3.55%
9.08
2.63
43.92% 53.21%
255.3B
57.2B
10.06% 52.68%
15.4
4.47
35.88% 197.59%
163.4B
46.7B
4.09% 51.76%
24.47
3.5
2.79% 223.53%
MID-CAP
5.5B
4.4B
-19.87% -8.47%
-46.93
1.26
1.80% 57.67%
SMALL-CAP
1.9B
628.4M
9.16% -55.02%
-4.08
3.1
64.35% -18.14%
1.9B
659.0M
7.90% 20.00%
32.36
2.95
16.78% -53.92%
1.5B
-
12.61% -60.46%
-0.54
1.95
-4.11% -144.36%
1.2B
112.7M
0.93% -22.57%
-10.75
7.76
-54.94% 40.20%
1.1B
3.1M
15.39% -57.51%
-3.57
108.75
-77.09% -12.24%
1.0B
23.5M
-0.88% 26.78%
-12.31
166.87
243.57% -1.04%
945.9M
373.2M
-2.73% -20.60%
4.56
2.34
-0.39% -38.45%
283.2M
49.7M
-17.79% -51.74%
-8.71
5.67
28.95% 32.80%
68.8M
2.6B
-43.99% -88.43%
-0.03
0.02
-13.88% -4855.92%

Financials for Horizon Pharma

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-2.9%3,7013,8133,7693,2262,957
Gross Profit-3.3%2,7812,8752,8602,4322,242
Operating Expenses3.8%2,1042,0271,9631,8891,692
  S&GA Expenses2.4%1,5671,5301,4871,4461,324
  R&D Expenses4.7%461441477432362
Earnings Before Taxes-22.8%584756807463481
Net Income-24.9%574765862534552
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets2.0%9,0288,8538,7408,6788,609
  Current Assets6.5%3,4123,2032,9482,8002,414
    Cash Equivalents12.6%2,1311,8931,6431,5801,069
  Inventory-6.6%190204227226237
  Net PPE5.1%318302295292286
  Goodwill0%1,0111,0111,0671,0671,069
  Current Liabilities8.8%861791825887854
  Long Term Debt-0.1%2,5652,5672,5692,5712,574
    LT Debt, Current0%1616161616
    LT Debt, Non Current-0.1%2,5492,5512,5532,5552,558
Shareholder's Equity1.8%5,0344,9464,8184,6724,450
  Retained Earnings3.8%606584523319145
  Additional Paid-In Capital1.0%4,4254,3814,3154,3734,311
Accumulated Depreciation12.7%5448423637
Shares Outstanding-0.7%229230229227227
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-3.2%1,3701,4151,2551,035907
  Share Based Compensation-5.0%186196205219203
Cashflow From Investing47.5%-121.77-231.85-305.34-2,994.11-3,022.70
Cashflow From Financing-94.5%-177.28-91.16-109.111,4701,465

Risks

What is the probability of a big loss on HZNP?

44.6%


Probability that Horizon Pharma stock will be more than 20% underwater in next one year

34.6%


Probability that Horizon Pharma stock will be more than 30% underwater in next one year.

10%


Probability that Horizon Pharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does HZNP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Horizon Pharma was unfortunately bought at previous high price.

Returns

Cumulative Returns on HZNP

44.5%


10-Year Cumulative Returns

25.9%


7-Year Cumulative Returns

47.7%


5-Year Cumulative Returns

46.7%


3-Year Cumulative Returns

What are the long-term rolling returns for HZNP?

FIve years rolling returns for Horizon Pharma.

Which funds bought or sold HZNP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
REDUCED
-26.5
-191,000
252,000
0.01%
2022-11-22
CVA Family Office, LLC
REDUCED
-83.33
-2,000
-
-%
2022-11-21
FourThought Financial, LLC
ADDED
110.64
7,000
18,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-2.84
-7,268,000
22,264,000
0.04%
2022-11-21
Parallax Volatility Advisers, L.P.
NEW
-
703,000
703,000
-%
2022-11-18
Ambassador Advisors, LLC
ADDED
15.62
-202,000
1,758,000
0.42%
2022-11-18
Industrial Alliance Investment Management Inc.
REDUCED
-38.55
-6,567,000
5,986,000
0.18%
2022-11-17
M&T Bank Corp
REDUCED
-51.83
-1,029,000
1,321,000
0.01%
2022-11-17
CENTRAL TRUST Co
REDUCED
-24.94
-1,122,000
1,564,000
0.05%
2022-11-16
Front Row Advisors LLC
NEW
-
6,000
6,000
-%

1–10 of 41

Latest Funds Activity

Are funds buying HZNP calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own HZNP

Horizon Pharma News

MarketWatch

The S&P 500 is on the cusp of breaking through a level that might spell the end of the bear market.10 hours ago

Baystreet.ca

HZNP Fair Value

Recent SEC filings of Horizon Pharma

View All Filings
Date Filed Form Type Document
Nov 29, 2022
8-K
Current Report
Nov 14, 2022
3
Insider Trading
Nov 02, 2022
8-K
Current Report
Nov 02, 2022
4
Insider Trading
Nov 02, 2022
10-Q
Quarterly Report
Oct 25, 2022
CT ORDER
CT ORDER
Oct 07, 2022
8-K
Current Report

Latest Insider Trading transactions for HZNP

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-01
Pasternak Andy
SOLD FOR TAXES
-347,680
63.18
-5,503
EVP and Chief Business Officer
2022-11-01
Pasternak Andy
ACQUIRED
-
-
12,421
EVP and Chief Business Officer
2022-08-04
Clayton Sean M.
BOUGHT
49,669.1
66.67
745
EVP, General Counsel
2022-07-29
Pasternak Andy
SOLD
-400,483
82.5739
-4,850
EVP and Chief Business Officer
2022-07-20
Thompson Elizabeth H.Z.
SOLD
-502,945
85
-5,917
EVP, Research & Development
2022-07-19
Thompson Elizabeth H.Z.
SOLD
-7,653.4
85.0378
-90
EVP, Research & Development
2022-07-07
Thompson Elizabeth H.Z.
SOLD
-6,970.82
85.01
-82
EVP, Research & Development
2022-06-10
Pasternak Andy
SOLD
-65,044.3
85.36
-762
EVP and Chief Business Officer
2022-06-03
Walbert Timothy P
SOLD
-2,308,470
92.3387
-25,000
Chairman, President and CEO
2022-06-03
Walbert Timothy P
ACQUIRED
553,500
22.14
25,000
Chairman, President and CEO

1–10 of 50

Timothy P. Walbert
1890
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

HZNP Income Statement

2022-09-30
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Net sales$ 925,359$ 1,036,992$ 2,687,015$ 2,211,946
Cost of goods sold234,132251,640679,410553,003
Gross profit691,227785,3522,007,6051,658,943
OPERATING EXPENSES:    
Research and development114,05889,549320,436244,076
Acquired in-process research and development and milestones19,0004,00019,00047,000
Selling, general and administrative397,563360,2601,168,5181,047,456
Impairment of goodwill  56,171 
Impairment of long-lived asset   12,371
Gain on sale of asset   (2,000)
Total operating expenses530,621453,8091,564,1251,348,903
Operating income160,606331,543443,480310,040
OTHER EXPENSE, NET:    
Interest expense, net(22,480)(22,977)(65,145)(59,018)
Foreign exchange loss(768)(476)(320)(1,363)
Other (expense) income, net(2,277)(849)(5,408)2,113
Total other expense, net(25,525)(24,302)(70,873)(58,268)
Income before benefit for income taxes135,081307,241372,607251,772
Benefit for income taxes(758)(19,302)(28,467)(109,537)
Net income$ 135,839$ 326,543$ 401,074$ 361,309
Net income per ordinary share—basic$ 0.59$ 1.44$ 1.75$ 1.61
Weighted average ordinary shares outstanding—basic230,333,287226,096,747229,820,406225,053,704
Net income per ordinary share—diluted$ 0.58$ 1.38$ 1.70$ 1.54
Weighted average ordinary shares outstanding—diluted235,385,570236,198,789235,923,030235,256,424
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX    
Interest rate swap contracts designated as cash flow hedges$ 23,874 $ 25,885 
Pension and other post-employment benefit plan remeasurements250 28$ (287)
Foreign currency translation adjustments(1,573)$ (514)(3,466)(1,100)
Other comprehensive income (loss)22,551(514)22,447(1,387)
Comprehensive income$ 158,390$ 326,029$ 423,521$ 359,922

HZNP Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
CURRENT ASSETS:  
Cash and cash equivalents$ 2,130,527$ 1,580,317
Restricted cash4,7433,839
Accounts receivable, net646,386632,775
Inventories, net190,258225,730
Prepaid expenses and other current assets440,095357,106
Total current assets3,412,0092,799,767
Property, plant and equipment, net317,692292,298
Developed technology and other intangible assets, net2,757,6942,960,118
In-process research and development810,000880,000
Goodwill1,010,5381,066,709
Deferred tax assets, net516,317538,098
Other long-term assets203,612140,738
Total assets9,027,8628,677,728
CURRENT LIABILITIES:  
Accounts payable32,11330,125
Accrued expenses and other current liabilities457,288523,015
Accrued trade discounts and rebates355,213317,431
Long-term debt-current portion16,00016,000
Total current liabilities860,614886,571
LONG-TERM LIABILITIES:  
Long-term debt, net2,549,1402,555,233
Deferred tax liabilities, net385,121390,455
Other long-term liabilities199,300173,076
Total long-term liabilities3,133,5613,118,764
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:  
Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at September 30, 2022 and December 31, 2021; 229,076,182 and 227,760,936 shares issued at September 30, 2022 and December 31, 2021, respectively; and 228,691,816 and 227,376,570 shares outstanding at September 30, 2022 and December 31, 2021, respectively2323
Treasury stock, 384,366 ordinary shares at September 30, 2022 and December 31, 2021(4,585)(4,585)
Additional paid-in capital4,424,5094,373,337
Accumulated other comprehensive income (loss)7,460(14,987)
Retained earnings606,280318,605
Total shareholders’ equity5,033,6874,672,393
Total liabilities and shareholders' equity$ 9,027,862$ 8,677,728